CD8A and lung cancer: The CD4/CD8 ratio was lower in T cells at resistance in both patients (Supplementary Fig. 7d), as it was the case for the mouse EGFR TL and Kras lung cancer models (Fig. 1a) In the anti-PD-1-resistant samples, we noted increased effector memory CD8 T cells (CCR7−CD45RA−) as compared with untreated samples (Supplementary Fig. 7d).